The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The Pre-MEASURE study: How does pretransplant IDH1 and IDH2 MRD affect posttransplant outcomes in patients with AML?
Featured:
Gege GuiThe AML Hub spoke to Gege Gui, National Institutes of Health, Maryland, US. We asked, How does pretransplant IDH1 and IDH2 measurable residual disease (MRD) affect posttransplant outcomes in patients with acute myeloid leukemia (AML)?
The Pre-MEASURE study: How does pretransplant IDH1 and IDH2 MRD affect posttransplant outcomes in patients with AML?
Gui provides an overview of the Pre-MEASURE study, a retrospective study assessing the impact of MRD, detected by next-generation sequencing, on posttransplant outcomes in patients with AML who are in first complete remission prior to allogeneic hematopoietic stem cell transplantation using a variety of MRD markers. She then discusses how pretransplant IDH1 and IDH2 MRD affect outcomes, and how these mutations compare with NMP1 and FLT3-internal tandem duplication mutations as MRD markers. Finally, Gui highlights the MEASURE study, which aims to validate these findings prospectively and optimize prognostication using MRD for patients with AML.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
